Abstract
Various pharmacological options have been developed for TTR cardiac amyloidosis (TTR-CA), targeting different phases of the disease process. Tafamidis is a stabilizer of the TTR molecule that reduces CV mortality and CV-related hospitalization in patients with either wild-type or hereditary TTR CM. Echocardiography is an important tool in the diagnosis and follow-up of patients with TTR-CA, however, no echocardiographic markers of response to treatment with Tafamidis have been identified to date.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
